Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 8/20 | 0.61 |
| ▸ | ECE1 | P42892 | 6/20 | 0.59 |
| ▸ | IL1RN | P18510 | 6/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427859 | 0.97 | ERAP2 (0.63) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30436333 | 0.93 | ECE1 (0.61) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30166489 | 0.93 | ECE1 (0.61) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30500405 | 0.93 | ECE1 (0.59) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL7047253 | 0.93 | KDM4E (0.58) | ECE1ACE | |
| SCHEMBL17274594 | 0.93 | KDM4E (0.58) | ECE1ACE | |
| SCHEMBL16057308 | 0.93 | KDM4E (0.58) | ECE1ACE | |
| SCHEMBL29519434 | 0.93 | KDM4E (0.58) | ECE1ACE | |
| SCHEMBL30506397 | 0.93 | ERAP2 (0.59) | ERAP2ECE1IL1RNERAP1ANPEP | |
| SCHEMBL31256996 | 0.92 | ERAP2 (0.62) | ERAP2ECE1IL1RNERAP1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743111-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | Rutgers, the State University of New Jersey (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-116064264-B | Method for producing recombinant host cells with improved tolerance to terpenes or essential oils containing terpenes and uses thereof | 中国科学院天津工业生物技术研究所 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025015118-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119193657-A | Method for rapidly and iteratively obtaining long-fragment DNA high-copy integrated saccharomyces cerevisiae recombinants | 大连工业大学 | 2024-12-27 | — | — | CN | disclosed |
| EP-4475853-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | Prendergast, Patrick T. (IE) | 2024-12-18 | — | — | EP | disclosed |
| CN-118813677-A | Application of GmKIN gene in regulating and controlling soybean phosphorus absorption and utilization efficiency and yield | 河南农业大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118804754-A | Compositions and methods for treating and preventing diseases using tirapazad salts | 帕特里克·T·普伦德加斯特 | 2024-10-18 | — | — | CN | disclosed |
| US-20240309069-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES | BYROCK TECHNOLOGIES LIMITED (IE) | 2024-09-19 | — | — | US | disclosed |
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (AU) | 2024-08-29 | — | — | US | disclosed |
| CN-117925634-A | Rice blast resistance and seed development related gene OsMAPKKK, coding protein and application thereof | 福建农林大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-115305254-B | Terpenoid chassis microorganism and engineering bacterium as well as construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2024-03-26 | — | — | CN | disclosed |
| CN-115322913-B | Recombinant saccharomyces cerevisiae for producing rose essential oil, and construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | disclosed |
| CN-116064264-A | Method for producing recombinant host cells with improved tolerance to terpenes or essential oils containing terpenes and uses thereof | 中国科学院天津工业生物技术研究所 | 2023-05-05 | — | — | CN | disclosed |
| CN-115322913-A | Recombinant saccharomyces cerevisiae for producing rose essential oil and construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2022-11-11 | — | — | CN | disclosed |
| CN-115305254-A | Terpenoid chassis microorganism and engineering bacterium as well as construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2022-11-08 | — | — | CN | disclosed |
| CN-108085262-B | Recombinant host cell with increased tolerance to terpenes or terpene-containing essential oils or increased terpene production, method for its production and use thereof | 中国科学院天津工业生物技术研究所 | 2022-08-05 | — | — | CN | disclosed |
| CN-110438099-B | Application of glycosyltransferase and related materials thereof in construction of engineering bacteria for producing ginsenosides Rb1 and Rg1 | 中国科学院天津工业生物技术研究所 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309069-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES | CTRL, SERPINB1, TIMP3 | ERAP2 106/4885ECE1 215/4885IL1RN 347/4885 |
| US-20240285653-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | TTR, MTPN, CYP24A1 | ERAP2 1384/4885ECE1 2740/4885IL1RN 297/4885 |
| US-20250064834-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | CYP24A1, IL23R, IL17A | ERAP2 2627/4885ECE1 2850/4885IL1RN 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.